Mouse Models of Human Brain Tumors: From Cage to Clinic David H. Gutmann, MD, PhD Donald O. Schnuck Family Professor Department of Neurology Washington.

Slides:



Advertisements
Similar presentations
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.
Advertisements

ALS Research Yesterday, Today and Tomorrow Heather D. Durham, PhD.
Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
TSC2 and Tuberous Sclerosis Complex Disease Laura Koontz Biology 169.
Presented by: Jacqueline Holt March 4th 2003
Phosphatase and Tensin Homolog Deleted on Chromosome 10
NF2 = gene Merlin = protein…a.k.a. schwannomin Tumor Suppressor Tumor suppressive ability comes from partial inhibition of Ras/Rac signaling (phosphorylates.
Neurofibromatosis 1 von Recklinghausen Syndrome Kristin Neitzke.
HKS Tumore HKS Tumore Epigenetics in glioma - MGMT, ABCB1 and ABCG2 methylation in glioma Moritz C. Oberstadt, PhD.
Pediatric Neurosurgical Neuropathology
Challenges and Considerations in Linking Adult and Pediatric CNS Malignancies Henry S. Friedman, MD The Brain Tumor Center at Duke.
In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
Research Techniques Made Simple: Induced Pluripotent Stem Cells in Dermatological Research Jason Dinella 1-3, Maranke I. Koster 1-3, and Peter J. Koch.
Brain Cancer By Cara Klingaman. Significance The brain is the center of thoughts, emotions, memory and speech. Brain also control muscle movements and.
Perspectives on CNS Malignancies Susan M. Staugaitis, M.D., Ph.D. Cleveland Clinic Foundation.
Malignant Melanoma and CDKN2A
CNS Neoplasm Dr. Raid Jastania, FRCPC Assistant Professor, Faculty of Medicine, Umm Alqura University Vice Dean, Faculty of Dentistry.
{ Targeting and killing of malignant gliomas by specific stem cells expressing a suicide gene.
Tumor genetics Minna Thullberg
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Cancer --an Overview  Cell Division  Hormones and Cancer  Malignant Transformation  Angiogenesis and Metastasis  Growth.
Cancer. Regulation of Cell Division Two sets of genes control cell division. –Proto-oncogenes. Code for proteins that promote the cell cycle and prevent.
Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.
TGF-β Receptor I/ALK5: An Attractive Therapeutic Target in Tumor Development By Jake Bridgers.
Preclinical Studies for Designing Rational Therapies for Epilepsy in Tuberous Sclerosis Complex Summit on Drug Discovery in TSC and Related Disorders Washington.
SHIP protein identified as a B-cell tumor suppressor Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally.
Molecular Biology of Cancer. CANCER TAKES TIME CANCER IS A DISEASE OF GENETIC MUTATIONS ACCUMULATION OF MANY MUTATIONS CAUSES CANCER.
NF2/Merlin: THE MAGIC OF MERLIN
Essentials of Biology Sylvia S. Mader
ROUND TABLE ON PRECLINICAL THERAPETUICS PANEL: Jon Kurie (M.D. Anderson) Eric Holland (MSKCC) Pier Paolo Pandolfi (MSKCC) Charles Sawyers (UCLA) Kevin.
BRG-1 in Cancer BRG-1 is an ATPase subunit of the SWI/SNF class of chromatin remodeling complexes It has been found mutated in a number of cancer cell.
INTRODUCTION TO PEDIATRIC ONCOLOGY Prof.Dr.Reha Cengizlier
Neurofibromatosis type 1. Biallelic NF1 inactivation leads to multiple symptoms.
Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.
Benign Versus Malignant Tumors
Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.
Cell Growth & Differentiation Vol. 10, , 1999 Inhibition of the Jun Kinase Pathway Blocks DNA Repair, Enhances p53-mediated Apoptosis and Promotes.
TSC1 and Facial Angiofibromas
Neurofibromatosis 1- NF1 BIOL 445 Alexa Schulman Gutmann et al
Honors Biology 2016 What is Cancer?. I. What is Cancer? A. Normally, cells are forced to undergo programmed cell death when: DNA is damaged Replication.
NF1 (Neurofibromatosis Type 1) Greg Hogan Ribbon Representation of NF1-333 Scheffzek, et al. (The EMBO Journal Vol. 17,pp , 1998) Structural.
NCI Initiatives to Develop Non-Clinical Models for Pediatric Oncology Malcolm A. Smith, MD, PhD 17 March 2004.
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
PTEN (Cowden Syndrome) /.../ sld083.htm.
Brain Tumors Mark Browning, M.D. IUSME. Differential Diagnosis includes: Primary CNS tumor Most common primary sites of brain mets: – Lung – Breast.
Pathology 430/827 Bladder cancer Etiology, classification, and diversity David M. Berman, MD, PhD Pathology and Molecular Medicine Queen’s Cancer Research.
Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.
Paige Myers & Mahek Shah.  Cancer is a disease in which the DNA of cells becomes damaged or changed and the affected cells do not respond to apoptosis.
Tuberous Sclerosis Abdullah M. Al-Olayan MBBS, SBP, ABP
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.
Colon cancer: the second leading cause of cancer deaths in the U.S. Polyps, the first stage In tumor development
Chapter 7 Neoplasia.
Northern Virginia National Society of Black Engineers Jr. Chapter Bio-Medical Competitio n.
Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.
La nuova biologia.blu Anatomia e fisiologia dei viventi S
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
Neurofibromatosis 1 Valerie Khodush March 27, 2007
NF1 Low-Grade Glioma Synodos
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Pediatric Neurosurgical Neuropathology
Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,
PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease
Cancer stem cells and their application into targeted therapy for cancer Mol. Bio. Lab Park Ji Won Supervisor ; Dae Youn Hwang.
PTEN Tumor Suppressor Extraordinaire
PTEN Tumor Suppressor and Cancer
Neurofibromatosis Eldar Kurtovic School of Engineering
Molecular Pathogenesis of Low-Grade Glioma
Steve S.W. Han, Luis A. Williams, Kevin C. Eggan  Neuron 
NF GEMMs Already! The Power and Promise of Mouse Tumor Models
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Presentation transcript:

Mouse Models of Human Brain Tumors: From Cage to Clinic David H. Gutmann, MD, PhD Donald O. Schnuck Family Professor Department of Neurology Washington University School of Medicine Director, Neurofibromatosis Center Co-Director, Neuro-Oncology Program © Washington University, 2009

Brain Tumors Leading cause of cancer-related death in children 4 th leading cause of cancer-related death in adults © Washington University, 2009

GeneChromosomeProtein Cyclin-dependent kinase inhibitor 2A 9pp16 Cyclin-dependent kinase inhibitor 2B 9pp15 Cyclin-dependent kinase 4 12qcdk4 Epidermal growth factor receptor 7qEGF-R Murine double minutes 12qMDM2 Phosphatase and tensin homology 10qPTEN p14 alternative reading frame 9pp14-ARF Retinoblastoma 1 13qRb TP53 17pp53 Tumor gradep5317p LOH10q LOHEGF-R amp WHO grade I71% 0% 0% 0% WHO grade II63% 0% 0% 0% WHO grade III63% 31% 13% 6% WHO grade IV68% 26% 38% 21% © Washington University, 2009

Limited insights into the molecular and cellular changes critical for tumor formation or continued growth Paleo-neuro-oncology © Washington University, 2009

sporadic cancer cancer predisposition syndrome loss of tumor suppressor gene function increased cell proliferation CANCER © Washington University, 2009

Familial syndromes associated with nervous system tumors SyndromeGenes Nervous system tumors von Hippel-LindauvHL (3p25-26)hemangioblastoma Tuberous sclerosis complexTSC1 (9p34) TSC2 (16p13)subependymal giant cell astrocytoma Li-Fraumenip53 (17p13)astrocytoma primitive neuroectodermal tumor Neurofibromatosis 1NF1 (17q11)optic pathway glioma, astrocytoma neurofibroma Neurofibromatosis 2NF2 (22q12)schwannoma, meningioma ependymoma © Washington University, 2009

15-20% of children with NF1 Typically young children WHO grade I pilocytic astrocytoma Commonly involving optic pathway Composed of GFAP- immunoreactive (glial) cells Brain Tumors in NF1 © Washington University, 2009

Neurofibromatosis type 1 as a model system for understanding the molecular and cellular pathogenesis of glioma? Most common inherited genetic mutation in pediatric low-grade glioma One of the most common genetic mutations in adult high-grade glioma (TCGA) © Washington University, 2009

+/- -/- +/+ +/- wild-type viable embryonic lethal Nf1 Nf1 gene neo E no gliomas no neurofibromas Brannan C. et al., Genes & Development 1994 Jacks T. et al., Nature Genetics 1994 © Washington University, 2009

Nf1 gene LoxP Cre recombinase disrupted Nf1 gene LoxP Zhu Y. et al., Genes & Development 2001 © Washington University, 2009

Bajenaru ML, Mol Cell Biol LoxP hGfap promoterCreIRESnLacZ Nf1 flox alleles Nf1-deficient normal NO BRAIN TUMORS © Washington University, 2009

NF1+/- (body) NF1-/- (tumor) © Washington University, 2009 Nf1-deficient astrocytes Nf1+/- LoxP hGfap promoterCreIRES nLacZ Nf1 flox allele Nf1 mut allele neo R Bajenaru ML, Cancer Res OPTIC GLIOMAS

Opportunities 1.Identify new targets for therapeutic drug design 2.Determine why certain therapies fail 3.Evaluate new therapies in preclinical models © Washington University, 2009

Nf1-deficient normal Nf1-deficient astrocytes Nf1+/- NO TUMOR TUMOR contribution(s) of other cell types in the tumor microenvironment © Washington University, 2009

Appropriate stromal cells and signals Susceptible preneoplastic cells © Washington University, 2009

1. What stromal cell types and molecular signals drive NF1 brain tumor cell growth? normal Enhance tumor growth by secreting cytokines and growth factors Increase tumor invasiveness Evade immune surveillance Bajenaru ML, Annals of Neurology 2005 © Washington University, 2009 MICROGLIA

1.Nf1+/-, but not wild-type, microglia promote Nf1-/- astrocyte proliferation in vitro 2.Nf1+/- microglia elaborate paracrine factors that promote Nf1-/- astrocyte proliferation in vitro brain microglia/astrocyte co-cultures brain microglia cultures (Nf1+/+ or Nf1+/-) culture supernatant Daginakatte & Gutmann, Human Mol. Genet © Washington University, 2009

equilibrationenhancementelimination © Washington University, 2009 “specialized” microglia

tumor elimination promote tumor growth endothelial cells CSCs glioma cells © Washington University, 2009

blood vessel cancer stem cells stromal cells differentiated tumor cells endothelial cells Future targeted therapies © Washington University, 2009 microglia microglia-produced growth factors

cell growth GDP ras GTP ras neurofibromin “active”“inactive” cell growth “ON”“OFF” X cell growth neurofibromin GDP GTP © Washington University, Evaluate why certain therapies fail

K-RASH-RASN-RAS Blocked by FTIs Not blocked by FTIs neurofibromin X cell growth farnesyltransferase inhibitors GDP GTP RAS “active” “inactive” © Washington University, 2009

treatment vehicle week old Nf1+/- GFAP CKO mice © Washington University, Evaluate new therapies in preclinical models

Treatment with chemotherapy used for children with low- grade brain tumors blocks mouse optic glioma tumor growth in vivo © Washington University, 2009

Mechanism of action Target validation “Off-target” effects Effect on normal brain © Washington University, 2009

PATIENTS molecular & cellular targets blood vessel cancer stem cells stromal cells differentiated tumor cells endothelial cells targeted treatment strategies surrogate outcome measurements mouse models © Washington University, 2009